This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
home:protocol:olmesartan:kidney_disease [08.13.2019] – [Animal studies] sallieq | home:protocol:olmesartan:kidney_disease [08.13.2019] – [Benefits of olmesartan for patients with kidney disease] sallieq | ||
---|---|---|---|
Line 7: | Line 7: | ||
- | ===== Subclinical kidney infection ===== | ||
- | Subclinical - that is to say, undetected or undetectable - kidney disease is common in patients with [[home: | ||
- | |||
- | Once patients activate the [[home: | ||
Line 47: | Line 43: | ||
" | " | ||
- | ===== Benefits | + | |
+ | ===== Subclinical kidney infection ===== | ||
+ | |||
+ | Subclinical - that is to say, undetected or undetectable - kidney disease is common in patients with [[home: | ||
+ | |||
+ | Once patients activate the [[home: | ||
+ | ===== Olmesartan benefits | ||
According to a 2008 commentary appearing in //Nature//: | According to a 2008 commentary appearing in //Nature//: |